Latest Breaking News On - Kent hawryluk - Page 3 : comparemela.com

Long-Acting PTH Prodrug Granted Orphan Status for Hypoparathyroidism

The FDA has granted Orphan Drug designation to MBX 2109 for the treatment of hypoparathyroidism.

Kent hawrylukDrug administrationOrphan drug

Slone Partners Places Richard B Bartram as Chief Financial Officer at MBX Biosciences

South Riding, VA (PRWEB) April 26, 2022 Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has

Kent hawrylukRichardb bartramRick bartramLeslie lovelessBiosciences incEnterprise associatesMichigan state universityFrazier life sciencesSlone partnersChief financial officerEsperion therapeuticsChief executive officerCertified publicPeople are our scienceSlone partnerPrecision endocrine peptides

Carmel Drug Discovery Company Appoints Chief Medical Officer

Carmel Drug Discovery Company Appoints Chief Medical Officer
insideindianabusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideindianabusiness.com Daily Mail and Mail on Sunday newspapers.

Kent hawrylukMary jane geigerMary janeRegeneron pharmaceuticalsகேண்ட் ஹவிரயிலுக்மேரி ஜேன் கைகர்மேரி ஜேன்

MBX Biosciences Appoints Mary Jane Geiger, M D , Ph D , as Chief Medical Officer

Posted on 344 MBX Biosciences, a drug discovery company focused on rare endocrine diseases, today announced the appointment of Mary Jane Geiger, M.D., Ph.D., FACP, FAHA, to the newly created role of chief medical officer. Dr. Geiger will oversee MBX’s global clinical drug development, bringing more than 20 years’ experience in clinical drug development and supporting multiple successful drug registrations. “Mary Jane’s range of experience taking treatments through clinical studies to registration makes her an ideal addition to our team,” said Kent Hawryluk, president and chief executive officer of MBX Biosciences. “Her demonstrated creativity in clinical trial design and strong clinical research background complement our organization’s expertise. She will play a leading role in MBX’s transition into a clinical-stage company.”

United statesMarquette universityMedical college of wisconsinKent hawrylukMary jane geigerMary janeEli lillyIan stoneRegeneron pharmaceuticalsCanale communicationsCollege of wisconsinSafety research consortiumDimarchi indiana universityEnterprise associatesDuke university medical centerLilly diabetes